ReDO_DB: the repurposing drugs in oncology database.

Autor: Pantziarka P; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; The George Pantziarka TP53 Trust, London, UK., Verbaanderd C; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Sukhatme V; GlobalCures Inc., Newton, MA 02459 USA., Rica Capistrano I; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Crispino S; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Gyawali B; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115 USA., Rooman I; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.; Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium., Van Nuffel AM; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Meheus L; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Sukhatme VP; GlobalCures Inc., Newton, MA 02459 USA.; Emory University School of Medicine, Atlanta, GA 30322 USA., Bouche G; The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.

Publikováno v: Ecancermedicalscience [Ecancermedicalscience] 2018 Dec 06; Vol. 12, pp. 886. Date of Electronic Publication: 2018 Dec 06 (Print Publication: 2018).

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Autor: Van Nuffel AM; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Sukhatme V; GlobalCures, Inc, Newton, MA 02459, USA., Pantziarka P; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium ; The George Pantziarka TP53 Trust, London KT1 2JP, UK., Meheus L; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Sukhatme VP; GlobalCures, Inc, Newton, MA 02459, USA ; Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, MA 02215, USA., Bouche G; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.

Publikováno v: Ecancermedicalscience [Ecancermedicalscience] 2015 Feb 24; Vol. 9, pp. 513. Date of Electronic Publication: 2015 Feb 24 (Print Publication: 2015).

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Autor: Benteyn D; Laboratory of Molecular & Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium., Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A

Publikováno v: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2013 Nov 19; Vol. 2, pp. e134. Date of Electronic Publication: 2013 Nov 19.

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL).

Autor: Benteyn D; Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology and Dendritic Cell Bank, Vrije Universiteit Brussel, 1090 Brussels, Belgium., Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A

Publikováno v: BioMed research international [Biomed Res Int] 2013; Vol. 2013, pp. 976383. Date of Electronic Publication: 2013 Jan 03.

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.

Autor: Van Nuffel AM; Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Belgium., Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2012 Jul; Vol. 61 (7), pp. 1033-43. Date of Electronic Publication: 2011 Dec 10.